Gain Therapeutics, Inc.
GANXNASDAQHealthcare● Active
$1.69
$-0.01(-0.59%)
Market Cap$72085324
P/E Ratio—
52W High$4.34
52W Low$1.41
Gain Therapeutics, Inc. (GANX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GANX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.13
Est. -$0.13 · +0.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
✓ 3-Quarter EPS Beat Streak
GANX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.14 | — | — | — | $0.00B | — |
| — Q2 FY2026 | May 11, 2026 | -$0.13 | -$0.13 | +0.0% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$0.14 | -$0.11 | +21.4% | — | $0.00B | — |
| — Q4 FY2025 | Nov 12, 2025 | -$0.15 | -$0.15 | +0.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.17 | -$0.19 | -11.8% | — | — | — |
| — Q2 FY2025 | May 14, 2025 | -$0.16 | -$0.16 | +0.0% | — | $0.00B | — |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.18 | -$0.11 | +38.9% | — | — | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.23 | -$0.17 | +26.1% | — | $0.00B | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.14
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026
EPS Actual
-$0.13
EPS Est.
-$0.13
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$0.11
EPS Est.
-$0.14
EPS Surpr.
+21.4%
Revenue
—
Q4 FY2025
Nov 12, 2025
EPS Actual
-$0.15
EPS Est.
-$0.15
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.17
EPS Surpr.
-11.8%
Revenue
—
Q2 FY2025
May 14, 2025
EPS Actual
-$0.16
EPS Est.
-$0.16
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.18
EPS Surpr.
+38.9%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.17
EPS Est.
-$0.23
EPS Surpr.
+26.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q3 FY2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q2 FY2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q1 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q4 FY2026 | $-0.14 | $-0.14 | $-0.14 | 1 |
| Q3 FY2026 | $-0.15 | $-0.14 | $-0.13 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +0.0% | $1.82 | $1.82 | +0.00% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +21.4% | $1.96 | $1.89 | -3.57% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +0.0% | $2.68 | $2.95 | +10.07% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -11.8% | $1.46 | $1.53 | +4.79% |
| ▲ Q2 FY2025 | May 14, 2025 | +0.0% | $1.93 | $1.86 | -3.63% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +38.9% | $2.09 | $2.07 | -0.96% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +26.1% | $2.03 | $1.75 | -13.79% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -35.5% | $0.95 | $0.97 | +1.52% |
Q2 FY2026+0.00%
Report Date
May 11, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.82
Price After
$1.82
Q1 FY2026-3.57%
Report Date
Mar 26, 2026
EPS Beat/Miss
+21.4%
Price Before
$1.96
Price After
$1.89
Q4 FY2025+10.07%
Report Date
Nov 12, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.68
Price After
$2.95
Q3 FY2025+4.79%
Report Date
Aug 12, 2025
EPS Beat/Miss
-11.8%
Price Before
$1.46
Price After
$1.53
Q2 FY2025-3.63%
Report Date
May 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.93
Price After
$1.86
Q1 FY2025-0.96%
Report Date
Mar 27, 2025
EPS Beat/Miss
+38.9%
Price Before
$2.09
Price After
$2.07
Q4 FY2024-13.79%
Report Date
Nov 14, 2024
EPS Beat/Miss
+26.1%
Price Before
$2.03
Price After
$1.75
Q3 FY2024+1.52%
Report Date
Aug 8, 2024
EPS Beat/Miss
-35.5%
Price Before
$0.95
Price After
$0.97
Avg Beat Reaction-1.98%
Avg Miss Reaction+3.16%
Beat Rate6 / 8 quarters
Largest Move-13.79% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GANX ends December
Gain Therapeutics, Inc. (GANX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.13 (in line with the analyst consensus of $-0.13). GANX has beaten EPS estimates for 3 consecutive quarters. The next GANX earnings date is expected around September 1, 2026.
Each quarter, investors track GANX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GANX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GANX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GANX earnings · 4 questionsGain Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. GANX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GANX historically reports after market close (AMC).
GANX earnings datewhen is GANX earningsGANX next earnings datewhen does GANX report earningsGANX earnings calendar
▸ Source: FMP · Gain Therapeutics, Inc. SEC filings · US GAAP · Gain Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026